News

Check category

All News

The Food and Drug Administration issued a public notice for the approval of the review and approval of clinical trials for drug adjustments (draft for comments)
The Food and Drug Administration issued a public notice for the approval of the review and approval of clinical trials for drug adjustments (draft for comments)
In order to implement the requirements of the General Office of the CPC Central Committee and the General Office of the State Council on the Opinions on Deepening the Reform of the Examination and Approval System and Encouraging the Innovation of Pharmaceutical Devices, the Food and Drug Administration has drafted the “Notice on Adjusting the Examination and Approval of Clinical Trials for Drugs” (Consultation Draft) ), is now open for comments and suggestions.
See more information
In order to implement the requirements of the General Office of the CPC Central Committee and the General Office of the State Council on the Opinions on Deepening the Reform of the Examination and Approval System and Encouraging the Innovation of Pharmaceutical Devices, the Food and Drug Administration has drafted the “Notice on Adjusting the Examination and Approval of Clinical Trials for Drugs” (Consultation Draft) ), is now open for comments and suggestions.
The Food and Drug Administration has issued the "Non-Clinical Research Quality Management Regulations"
The Food and Drug Administration has issued the "Non-Clinical Research Quality Management Regulations"
In order to ensure the quality of non-clinical evaluation of drugs and to protect the public, recently, the State Food and Drug Administration issued a new revised Code of Quality Management for Non-Clinical Research of Drugs (Order No. 34 of the State Food and Drug Administration) (below) Referred to as "the norm").
See more information
In order to ensure the quality of non-clinical evaluation of drugs and to protect the public, recently, the State Food and Drug Administration issued a new revised Code of Quality Management for Non-Clinical Research of Drugs (Order No. 34 of the State Food and Drug Administration) (below) Referred to as "the norm").
China has broken the monopoly of foreign patent drugs in the fields of lung cancer and leukemia, and the new drug creation specializes in "bumper harvest"
China has broken the monopoly of foreign patent drugs in the fields of lung cancer and leukemia, and the new drug creation specializes in "bumper harvest"
Lung cancer, leukemia and other fields have broken foreign monopoly. The domestic small molecule targeted drug market has promoted the price reduction of foreign drugs in China by more than 50%...
See more information
Lung cancer, leukemia and other fields have broken foreign monopoly. The domestic small molecule targeted drug market has promoted the price reduction of foreign drugs in China by more than 50%...
Previous page
1

Copyright 2019 ©sdhopepharm.com All Rights Reserved       浙ICP备10036259号

Power by:300.cn

Copyright 2019 ©sdhopepharm.comnehe.com 

浙ICP备10036259号

Power by: 300.cn